{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70759"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que le Survodutide ?<\/h3>\n<p style=\"margin: 0;\"><strong>Survodutide<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 studies it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2230198-02-2 (survodutide ; couramment cit\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agoniste dual des r\u00e9cepteurs GLP-1 \/ glucagon \u00e0 longue dur\u00e9e d'action (peptide synth\u00e9tique acyl\u00e9 ; Boehringer Ingelheim BI 456906 ; co-d\u00e9velopp\u00e9 avec Zealand Pharma)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3,800 Da (avec acylation d'acide gras ; forme mature du peptide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Structure<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Peptide synth\u00e9tique co-agoniste de 29 acides amin\u00e9s avec des substitutions d'Aib con\u00e7ues pour la r\u00e9sistance \u00e0 la DPP-4 et une cha\u00eene acyle d'acide gras attach\u00e9e \u00e0 un r\u00e9sidu de lysine via un lien \u03b3-Glu. Substantiellement plus court que les agonistes doubles d\u00e9riv\u00e9s de l'oxyntomoduline (mazdutide ~39 aa) tout en pr\u00e9servant une activit\u00e9 \u00e9quilibr\u00e9e sur les r\u00e9cepteurs GLP-1\/glucagon.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes. Les peptides acyl\u00e9s peuvent se dissoudre plus lentement \u2014 pr\u00e9voyez un temps d'\u00e9quilibration suppl\u00e9mentaire.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que le Survodutide ?<\/h2>\n<p><strong>Survodutide<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist studies programme, alongside the parallel programmes that produced <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation. Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing. The current clinical signature of survodutide is the <strong>effet remarquable sur la fibrose h\u00e9patique dans la MASH (st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 la dysfonction m\u00e9tabolique)<\/strong> rapport\u00e9 dans l'essai de phase 2 \u2014 un r\u00e9sultat qui le distingue des autres agonistes doubles et triples ayant des effets similaires sur le poids corporel. Les donn\u00e9es de phase 2 sur l'ob\u00e9sit\u00e9 ont montr\u00e9 des r\u00e9ductions de poids corporel d'environ 19 % \u00e0 4,8 mg hebdomadaires sur 46 semaines, pla\u00e7ant le Survodutide dans la m\u00eame cat\u00e9gorie d'effet que le tirzepatide et \u00e0 la fronti\u00e8re du triple-agoniste retatrutide. Le Survodutide est actuellement en essais de phase 3 pour l'ob\u00e9sit\u00e9 (conception d'essai de type SURMOUNT) et la MASH. Le Survodutide n'est <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sibling dual GLP-1\/glucagon co-agonist, see our <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">Mazdutide<\/a> page produit ; pour le triple-agoniste qui ajoute le GIP, voir <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a>. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Co-agonisme double des r\u00e9cepteurs GLP-1 \/ Glucagon avec accent h\u00e9patique<\/h2>\n<p>Ce qui rend le Survodutide m\u00e9canistiquement distinct parmi les peptides m\u00e9taboliques double-agonistes est son <strong>ratio de puissance GLP-1\/glucagon relativement \u00e9quilibr\u00e9<\/strong> qui produit \u00e0 la fois des effets substantiels sur la d\u00e9pense \u00e9nerg\u00e9tique (le bras glucagon) et les effets canoniques de sati\u00e9t\u00e9\/glyc\u00e9mie du GLP-1, avec un accent particulier sur les r\u00e9sultats h\u00e9patiques :<\/p>\n<ul>\n<li><strong>Activation du r\u00e9cepteur GLP-1 \u2014 sati\u00e9t\u00e9, s\u00e9cr\u00e9tion d'insuline par les cellules \u03b2, vidange gastrique<\/strong> \u2014 Survodutide active le r\u00e9cepteur GLP-1 sur les cellules b\u00eata pancr\u00e9atiques (s\u00e9cr\u00e9tion d'insuline d\u00e9pendante du glucose, suppression du glucagon des cellules alpha), les neurones POMC du noyau arqu\u00e9 hypothalamique (r\u00e9gulation centrale de l'app\u00e9tit) et les aff\u00e9rences vagales gastriques (ralentissement de la vidange gastrique). Ce bras recoupe le m\u00e9canisme du semaglutide et la composante GLP-1 de tous les peptides incr\u00e9tines multi-agonistes.<\/li>\n<li><strong>Activation du r\u00e9cepteur du glucagon \u2014 mobilisation des lipides h\u00e9patiques, d\u00e9pense \u00e9nerg\u00e9tique, activation du tissu adipeux brun<\/strong> \u2014 La caract\u00e9ristique d\u00e9terminante commune avec <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">mazdutide<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">retatrutide<\/a> is glucagon-receptor agonism. In survodutide studies, this arm produces particularly strong hepatic lipid mobilisation \u2014 hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm&#8217;s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.<\/li>\n<li><strong>Ing\u00e9nierie de l'\u00e9quilibre des r\u00e9cepteurs et rapport de puissance des agonistes doubles<\/strong> \u2014 The pharmacological challenge in dual GLP-1\/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation protocols.<\/li>\n<\/ul>\n<p>The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide&#8217;s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Survodutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>MASLD\/MASH (maladie h\u00e9patique associ\u00e9e \u00e0 la dysfonction m\u00e9tabolique)<\/strong> \u2014 hepatic triglyceride content, ALT\/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide&#8217;s strongest signal and the basis for its dedicated MASH Phase 3 programme<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 mod\u00e8les pr\u00e9cliniques de rongeurs DIO, composition corporelle (DEXA\/IRM), tests de prise alimentaire, mesure de la d\u00e9pense \u00e9nerg\u00e9tique<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 contr\u00f4le glyc\u00e9mique, dynamique de suppression du glucagon, substituts d'HbA1c ; l'\u00e9quilibre des r\u00e9cepteurs modifi\u00e9s favorise une r\u00e9duction nette de la glyc\u00e9mie malgr\u00e9 la composante glucagon<\/li>\n<li><strong>Energy-expenditure and thermogenesis studies<\/strong> \u2014 d\u00e9pense \u00e9nerg\u00e9tique au repos, activation du tissu adipeux brun, expression des g\u00e8nes thermog\u00e9niques ; particuli\u00e8rement pertinent compte tenu de l'action du glucagon<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 comparaison directe avec l'autre agoniste double GLP-1\/glucagon <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">Mazdutide<\/a> (d\u00e9riv\u00e9 de l'oxyntomoduline, 39 aa), le double agoniste GLP-1\/GIP <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a>, et le triple agoniste <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a>; receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 effets sur la pression art\u00e9rielle, les profils lipidiques ; donn\u00e9es sur les r\u00e9sultats cardiovasculaires accumul\u00e9es \u00e0 partir des programmes de phase 2\/3<\/li>\n<li><strong>Pharmacologie de l'axe du glucagon<\/strong> \u2014 pharmacologie isol\u00e9e du r\u00e9cepteur du glucagon, dynamique de production h\u00e9patique de glucose, caract\u00e9risation de l'\u00e9quilibre de puissance entre les r\u00e9cepteurs du glucagon et du GLP-1<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 comparaison avec les agonistes simples GLP-1 (<a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a>) et pharmacologie combin\u00e9e de l'axe de l'amyline (<a href=\"https:\/\/medsbase.com\/fr\/cagrilintide\/\">Cagrilintide<\/a> + Semaglutide CagriSema).<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place du survodutide dans le paysage des peptides m\u00e9taboliques multi-agonistes, voir <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">Mazdutide<\/a> comme le co-agoniste double GLP-1\/glucagon fr\u00e8re, <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> comme le triple-agoniste qui ajoute le GIP, <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a> comme l'alternative double utilisant le GIP au lieu du glucagon, et <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> comme la r\u00e9f\u00e9rence mono-agoniste. Parcourez l'int\u00e9gralit\u00e9 <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles \u00e0 cycle prolong\u00e9, \u00e9tudes \u00e0 cohortes multiples, co\u00fbt le plus bas par mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3\u20134.8\u00a0mg weekly with a 4\u20136 month titration schedule, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Comparaison \u2014 Survodutide vs Mazdutide<\/h2>\n<p>Le Survodutide et <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">Mazdutide<\/a> are the two principal dual GLP-1 \/ glucagon co-agonist peptides in current literature. They share receptor pharmacology \u2014 both activate the GLP-1 and glucagon receptors, both lack GIP activity \u2014 but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Survodutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil des r\u00e9cepteurs<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (double)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (double)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 acides amin\u00e9s (compact)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 acides amin\u00e9s (d\u00e9riv\u00e9 de l'oxyntomoduline)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e9veloppeur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Boehringer Ingelheim + Zealand Pharma<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent Biologics (sous licence de Eli Lilly)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Code de d\u00e9veloppement<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BI 456906<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBI362 \/ LY3305677<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u00c9quilibre des r\u00e9cepteurs<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pr\u00e9dominance glucagon (effets h\u00e9patiques marqu\u00e9s)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pr\u00e9dominance GLP-1 (profil glyc\u00e9mique plus net)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 jours (une fois par semaine)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hebdomadaire (acyl\u00e9)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Signal clinique distinctif<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Am\u00e9lioration de la fibrose h\u00e9patique MASH (Phase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Premier double agoniste approuv\u00e9 (China NMPA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet sur le poids corporel<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~19 % (Phase 2, 46 sem)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317 % (Phase 3, 48 sem)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,3\u20134,8 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For MASH\/MASLD liver-disease studies, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For studies interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide&#8217;s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1\/glucagon co-agonist pharmacology \u2014 both are likely to remain in active studies and clinical development through this decade. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> Conservez les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congelez \u00e0 \u221220 \u00b0C. Le survodutide lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.9\u00a0mL delivers a 4.8\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>re\u00e7oit pas<\/strong> secouez pas \u2014 et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te (les peptides acyl\u00e9s se dissolvent plus lentement que les petits peptides non modifi\u00e9s). Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore, sans particules visibles. <strong>Apr\u00e8s reconstitution :<\/strong> conservez au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les cycles de gel-d\u00e9gel d\u00e9gradent l'int\u00e9grit\u00e9 du peptide. Jetez tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Survodutide used for in studies?<\/h3>\n<p>Survodutide is used in studies investigating MASLD\/MASH liver disease (its strongest distinctive signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), the sibling dual GLP-1\/glucagon mazdutide, and triple-agonist retatrutide. The pharmaceutical-grade survodutide sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi le Survodutide diff\u00e8re-t-il du Mazdutide ?<\/h3>\n<p>Both are dual GLP-1\/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH studies, survodutide is the canonical choice; for clean glycaemic-axis studies with minimal glucagon interference, mazdutide is preferred. <\/p>\n<h3>En quoi le Survodutide diff\u00e8re-t-il du Tirzepatide ?<\/h3>\n<p>Les deux sont des agonistes doubles des incr\u00e9tines, mais ils activent des seconds r\u00e9cepteurs diff\u00e9rents. Le Tirzepatide est GLP-1 + GIP (effet d'environ 22 % sur le poids corporel dans SURMOUNT-1). Le Survodutide est GLP-1 + glucagon (environ 19 % en Phase 2). Les deux combinaisons de r\u00e9cepteurs produisent des profils m\u00e9taboliques qualitativement diff\u00e9rents : le GIP ajoute une lipolyse des adipocytes dans des conditions de je\u00fbne ; le glucagon ajoute une d\u00e9pense \u00e9nerg\u00e9tique substantielle et une mobilisation des lipides h\u00e9patiques. Le Survodutide pr\u00e9sente le signal unique de fibrose-MASH en raison de son effet h\u00e9patique li\u00e9 au glucagon. <\/p>\n<h3>En quoi le Survodutide diff\u00e8re-t-il du Retatrutide ?<\/h3>\n<p>Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon \u2014 it is a triple agonist. Survodutide stops at the dual combination. Retatrutide&#8217;s Phase 2 body-weight effect (~24%) is larger than survodutide&#8217;s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For studies isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools. <\/p>\n<h3>What is the typical Survodutide dose?<\/h3>\n<p>Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3\u00a0mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8\u00a0mg weekly over approximately 24 weeks. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.9\u00a0mL equals a 4.8\u00a0mg clinical-equivalent dose. <\/p>\n<h3>Le Survodutide est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. <\/p>\n<h3>Comment le Survodutide doit-il \u00eatre stock\u00e9 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : conserv\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C pour les stocks de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : conserv\u00e9e au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer le Survodutide ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur le g\u00e2teau lyophilis\u00e9), agitez doucement et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te (les peptides acyl\u00e9s se dissolvent plus lentement que les petits peptides non modifi\u00e9s). Ne <strong>re\u00e7oit pas<\/strong> Secouez le flacon. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 2,0 mL de diluant, la concentration de travail est de 2,5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Survodutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Why is Survodutide particularly relevant for MASH studies?<\/h3>\n<p>Survodutide&#8217;s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published studies. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm&#8217;s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial \u2014 an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects. <\/p>\n<h3>Le composant glucagon provoque-t-il une hyperglyc\u00e9mie ?<\/h3>\n<p>Le classique \u201c paradoxe du glucagon \u201d s'applique au survodutide comme aux autres co-agonistes doubles GLP-1\/glucagon : le glucagon seul augmente la glyc\u00e9mie en stimulant la production h\u00e9patique de glucose, mais l'action dominante hypoglyc\u00e9miante du composant GLP-1 sur l'insuline et la suppression du glucagon au niveau des cellules b\u00eata et alpha l'emportent. Le ratio \u00e9quilibr\u00e9 d'activation des r\u00e9cepteurs du survodutide permet une r\u00e9duction nette de la glyc\u00e9mie malgr\u00e9 l'activation du r\u00e9cepteur du glucagon \u2014 les donn\u00e9es publi\u00e9es de la Phase 2 confirment une am\u00e9lioration du contr\u00f4le glyc\u00e9mique chez les cohortes de DT2 \u00e0 la dose d'entretien. <\/p>\n<h3>Does Survodutide cause side reported effects?<\/h3>\n<p>Le r\u00e9sultat le plus constant est gastro-intestinal, similaire aux autres peptides de l'axe GLP-1 \u2014 naus\u00e9es, suppression transitoire de l'app\u00e9tit et vidange gastrique retard\u00e9e sont dose-d\u00e9pendants et ont tendance \u00e0 s'att\u00e9nuer avec le long calendrier de titration utilis\u00e9 en Phase 2. Les r\u00e9sultats li\u00e9s au composant glucagon incluent des \u00e9l\u00e9vations modestes de la fr\u00e9quence cardiaque au repos et (rarement) des effets transitoires sur la pression art\u00e9rielle. La longue titration est en partie con\u00e7ue pour minimiser ces effets. <\/p>\n<h3>Quelle est la demi-vie du Survodutide ?<\/h3>\n<p>In preclinical and clinical studies, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue. <\/p>\n<h3>How long does Survodutide take to show effects in preclinical studies?<\/h3>\n<p>Les effets pharmacodynamiques aigus sur la tol\u00e9rance au glucose et la vidange gastrique sont d\u00e9tectables quelques heures apr\u00e8s la premi\u00e8re dose. Les effets sur le poids corporel dans les mod\u00e8les rongeurs DIO deviennent g\u00e9n\u00e9ralement significatifs statistiquement apr\u00e8s 1 \u00e0 2 semaines de doses hebdomadaires. Les effets sur le contenu en triglyc\u00e9rides h\u00e9patiques et la normalisation des ALT\/AST dans le MASLD\/MASH s'accumulent sur 8 \u00e0 16 semaines de dosage r\u00e9gulier. L'effet maximal sur la composition corporelle se d\u00e9veloppe sur 24 \u00e0 46 semaines, refl\u00e9tant la trajectoire de la Phase 2. <\/p>\n<h3>Puis-je commander du Survodutide pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le Survodutide dans le monde entier depuis notre r\u00e9seau d\u00e9di\u00e9 d'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles pour notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, MASH, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 Co-agoniste double GLP-1\/glucagon fr\u00e8re \u2014 ratio d'\u00e9quilibre des r\u00e9cepteurs alternatif<\/li>\n<li><a href=\"\/fr\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Agoniste triple GLP-1\/GIP\/glucagon \u2014 ajoute le GIP au profil double GLP-1\/glucagon<\/li>\n<li><a href=\"\/fr\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agoniste double GLP-1\/GIP \u2014 alternative double-agoniste utilisant le GIP au lieu du glucagon<\/li>\n<li><a href=\"\/fr\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agoniste simple GLP-1 \u2014 comparateur de base canonique<\/li>\n<li><a href=\"\/fr\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 Analogue de l'amylin \u2014 approche alternative de pharmacologie combin\u00e9e<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explorez le paysage des co-agonistes doubles GLP-1\/glucagon<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s multi-agonistes apparent\u00e9s incluant <a href=\"https:\/\/medsbase.com\/fr\/mazdutide\/\">Mazdutide<\/a> (co-agoniste double GLP-1\/glucagon fr\u00e8re), <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> (triple-agoniste), et <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a> (double GLP-1\/GIP). Guide comparatif : <a href=\"https:\/\/medsbase.com\/fr\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide \u2014 triple agoniste vs double agoniste<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Double agoniste des r\u00e9cepteurs GLP-1 + glucagon<br \/>\n\u2705 Peptide compact de 29 acides amin\u00e9s Boehringer\/Zealand (BI 456906)<br \/>\n\u2705 Signal fort de fibrose h\u00e9patique MASH en phase 2<br \/>\n\u2705 \u00c9quilibre des r\u00e9cepteurs favorisant le glucagon<br \/>\n\u2705 Administration hebdomadaire (demi-vie d'environ 6 jours)<\/p>\n<p><strong>Survodutide<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70984,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,6286],"class_list":["post-70759","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-survodutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70984"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70759"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70759"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70759"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}